🇺🇸 FDA
Patent

US 10617674

Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

granted A61KA61K31/415A61K9/0053

Quick answer

US patent 10617674 (Dosage regimen for the treatment of acute exacerbations of inflammatory conditions) held by MEREO BIOPHARMA 1 LIMITED expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MEREO BIOPHARMA 1 LIMITED
Grant date
Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/415, A61K9/0053, A61P, A61P11/00